3 results
The primary objective of the study is to descriptively characterize the single-dose and steadystatePharmacokinetics (PK) of diacerein (if quantifiable) and its active metabolite, rhein, after topical application of CCP-020 (diacerein 1% ointment)…
The primary objective of this study is to evaluate the long-term safety and tolerability of Diacerein 1% Ointment for 2 treatment cycles in subjects with EBS that were previously enrolled in studies CCP-020-301 or CCP-020-101.
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…